[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzawATRjySd7MFCaLNcggQj1c58-uy_mjkVv0lXPElYY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":82,"rows":89},"Children's National Research Institute",[4],119,false,52,3,76176,18,86,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Sickle Cell Disease",7,{"name":18,"count":9},"Rhabdomyosarcoma",{"name":20,"count":9},"Ewing Sarcoma",{"name":22,"count":9},"Wilms Tumor",{"name":24,"count":9},"Type 1 Diabetes",{"name":26,"count":9},"Autism Spectrum Disorder",{"name":28,"count":9},"Pain",{"name":30,"count":9},"Pediatric ALL",[32,37,42,47,52,57,62,67,72,77],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT02789228","Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors","2022-04-18","Tumor associated antigen lymphocytes",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05382637","Growth Hormone in a Patient With a Dominant-Negative GHR Mutation","2023-09-01","Somatropin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06429982","Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols","2025-12-01","Dexamethasone",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03180216","T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","2026-03","Virus Specific T cells",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT02229968","Efficacy of Amicar for Children Having Craniofacial Surgery","2028-01","Amicar",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05332067","Omalizumab Before Onset of Exacerbations","2028-01-01","Omalizumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07017816","A Phase 0\u002F1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.","2028-05-01","SGT-53",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04691622","Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","2028-08-30","Norovirus -specific T-cell (NST) therapy",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05238792","Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors","2028-10","Tumor-associated antigen-specific T cell",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05141058","T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients","2028-11-01","Coronavirus-specific T cell",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,130,155,176,194,221,239,257,282,304,326,357,375,397,421,443,466,509,527,576,598,616,641,659,677,704,731,764,793,819,837,855,883,901,927,951,977,1002,1029,1054],{"intervention":91,"totalTrials":92,"cells":93},"normal saline",2,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":123,"soonestReadout":55},[101,114],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":96,"conditions":109,"interventions":112},"NCT02532322","Efficacy of Acetaminophen in Posterior Fossa Surgery","WITHDRAWN",[85],"2018-06","2018-10","2015-11",[110,111],"Arnold-Chiari Malformation","Posterior Fossa Tumors",[113,91],"IV acetaminophen",{"nctId":53,"briefTitle":54,"status":115,"phases":116,"primaryCompletion":55,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"ACTIVE_NOT_RECRUITING",[85],"2028-03","2014-10",22,[121],"Craniosynostosis",[56,91],1,{"trials":125,"activeCount":96},[],{"trials":127,"activeCount":96},[],{"trials":129,"activeCount":96},[],{"intervention":61,"totalTrials":123,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":149,"PHASE4":151,"NA":153},{"trials":133,"activeCount":96},[],{"trials":135,"activeCount":96},[],{"trials":137,"activeCount":123,"soonestReadout":60},[138],{"nctId":58,"briefTitle":59,"status":139,"phases":140,"primaryCompletion":60,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":148},"RECRUITING",[85],"2028-03-01","2022-05-01",300,[145,146,147],"Asthma in Children","Atopy","Viral Upper Respiratory Infection",[61],{"trials":150,"activeCount":96},[],{"trials":152,"activeCount":96},[],{"trials":154,"activeCount":96},[],{"intervention":41,"totalTrials":123,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":170,"PHASE4":172,"NA":174},{"trials":158,"activeCount":96},[],{"trials":160,"activeCount":96},[],{"trials":162,"activeCount":123,"soonestReadout":40},[163],{"nctId":38,"briefTitle":39,"status":115,"phases":164,"primaryCompletion":40,"completion":165,"start":166,"enrollment":123,"conditions":167,"interventions":169},[85],"2028-09-01","2022-08-26",[168],"Growth Disorders",[41],{"trials":171,"activeCount":96},[],{"trials":173,"activeCount":96},[],{"trials":175,"activeCount":96},[],{"intervention":56,"totalTrials":123,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":179,"activeCount":96},[],{"trials":181,"activeCount":96},[],{"trials":183,"activeCount":123,"soonestReadout":55},[184],{"nctId":53,"briefTitle":54,"status":115,"phases":185,"primaryCompletion":55,"completion":117,"start":118,"enrollment":119,"conditions":186,"interventions":187},[85],[121],[56,91],{"trials":189,"activeCount":96},[],{"trials":191,"activeCount":96},[],{"trials":193,"activeCount":96},[],{"intervention":195,"totalTrials":123,"cells":196},"Daratumumab",{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":198,"activeCount":96},[],{"trials":200,"activeCount":96},[],{"trials":202,"activeCount":123,"soonestReadout":207},[203],{"nctId":204,"briefTitle":205,"status":139,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT06358638","Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody",[85],"2044-09","2054-09","2024-04-03",12,[15],[195,213,214],"Alemtuzumab","Sirolimus",{"trials":216,"activeCount":96},[],{"trials":218,"activeCount":96},[],{"trials":220,"activeCount":96},[],{"intervention":213,"totalTrials":123,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":224,"activeCount":96},[],{"trials":226,"activeCount":96},[],{"trials":228,"activeCount":123,"soonestReadout":207},[229],{"nctId":204,"briefTitle":205,"status":139,"phases":230,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":231,"interventions":232},[85],[15],[195,213,214],{"trials":234,"activeCount":96},[],{"trials":236,"activeCount":96},[],{"trials":238,"activeCount":96},[],{"intervention":214,"totalTrials":123,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":242,"activeCount":96},[],{"trials":244,"activeCount":96},[],{"trials":246,"activeCount":123,"soonestReadout":207},[247],{"nctId":204,"briefTitle":205,"status":139,"phases":248,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":249,"interventions":250},[85],[15],[195,213,214],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"trials":256,"activeCount":96},[],{"intervention":258,"totalTrials":123,"cells":259},"Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells",{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":280},{"trials":261,"activeCount":96},[],{"trials":263,"activeCount":123,"soonestReadout":268},[264],{"nctId":265,"briefTitle":266,"status":139,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":11,"conditions":271,"interventions":273},"NCT07172958","Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed\u002FRefractory Embryonal Tumors (SABRE)",[84],"2035-12","2038-12","2026-01-27",[18,20,272,22],"Neuroblastoma",[258],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":96},[],{"trials":281,"activeCount":96},[],{"intervention":46,"totalTrials":123,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":285,"activeCount":96},[],{"trials":287,"activeCount":123,"soonestReadout":45},[288],{"nctId":43,"briefTitle":44,"status":139,"phases":289,"primaryCompletion":45,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},[84],"2026-12-31","2024-10-01",50,[294],"Rhabdomyolysis",[46],{"trials":297,"activeCount":96},[],{"trials":299,"activeCount":96},[],{"trials":301,"activeCount":96},[],{"trials":303,"activeCount":96},[],{"intervention":81,"totalTrials":123,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":307,"activeCount":96},[],{"trials":309,"activeCount":123,"soonestReadout":80},[310],{"nctId":78,"briefTitle":79,"status":139,"phases":311,"primaryCompletion":80,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},[84],"2029-12-15","2021-10-19",24,[316],"SARS-CoV-2 Infection",[81],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":96},[],{"trials":323,"activeCount":96},[],{"trials":325,"activeCount":96},[],{"intervention":327,"totalTrials":123,"cells":328},"Multi-tumor antigen specific cytotoxic T lymphocytes",{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":330,"activeCount":96},[],{"trials":332,"activeCount":123,"soonestReadout":337},[333],{"nctId":334,"briefTitle":335,"status":139,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":210,"conditions":340,"interventions":347},"NCT06193759","Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)",[84],"2030-12-29","2032-12-29","2024-09-20",[341,342,343,344,345,346],"Medulloblastoma, Childhood","Atypical Teratoid\u002FRhabdoid Tumor of CNS","Embryonal Tumor With Multilayered Rosettes","Pineoblastoma","Embryonal Brain Tumor Not Otherwise Specified","Ependymoma",[327,348],"Group A Standard-of-Care Backbone Therapy",{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":96},[],{"trials":354,"activeCount":96},[],{"trials":356,"activeCount":96},[],{"intervention":348,"totalTrials":123,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":360,"activeCount":96},[],{"trials":362,"activeCount":123,"soonestReadout":337},[363],{"nctId":334,"briefTitle":335,"status":139,"phases":364,"primaryCompletion":337,"completion":338,"start":339,"enrollment":210,"conditions":365,"interventions":366},[84],[341,342,343,344,345,346],[327,348],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"trials":372,"activeCount":96},[],{"trials":374,"activeCount":96},[],{"intervention":36,"totalTrials":123,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":378,"activeCount":96},[],{"trials":380,"activeCount":123,"soonestReadout":35},[381],{"nctId":33,"briefTitle":34,"status":115,"phases":382,"primaryCompletion":35,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},[84],"2027-12","2016-10-12",28,[387],"Solid Tumors",[36],{"trials":390,"activeCount":96},[],{"trials":392,"activeCount":96},[],{"trials":394,"activeCount":96},[],{"trials":396,"activeCount":96},[],{"intervention":71,"totalTrials":123,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":400,"activeCount":96},[],{"trials":402,"activeCount":123,"soonestReadout":70},[403],{"nctId":68,"briefTitle":69,"status":139,"phases":404,"primaryCompletion":70,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":412},[84],"2028-10-30","2022-03-17",48,[409,410,411],"Viral Infection","Hematopoietic Stem Cell Transplantation (HSCT)","Primary Immunodeficiency Disorders (PID)",[71],{"trials":414,"activeCount":96},[],{"trials":416,"activeCount":96},[],{"trials":418,"activeCount":96},[],{"trials":420,"activeCount":96},[],{"intervention":76,"totalTrials":123,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":424,"activeCount":96},[],{"trials":426,"activeCount":123,"soonestReadout":75},[427],{"nctId":73,"briefTitle":74,"status":139,"phases":428,"primaryCompletion":75,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},[84],"2029-10","2021-11-17",36,[433],"Solid Tumor",[76],{"trials":436,"activeCount":96},[],{"trials":438,"activeCount":96},[],{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"intervention":51,"totalTrials":123,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":446,"activeCount":96},[],{"trials":448,"activeCount":123,"soonestReadout":50},[449],{"nctId":48,"briefTitle":49,"status":115,"phases":450,"primaryCompletion":50,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":457},[84],"2026-11","2017-02-15",32,[455,456],"Viral Infections","Bone Marrow Transplant Infection",[51],{"trials":459,"activeCount":96},[],{"trials":461,"activeCount":96},[],{"trials":463,"activeCount":96},[],{"trials":465,"activeCount":96},[],{"intervention":467,"totalTrials":92,"cells":468},"Nivolumab",{"EARLY_PHASE1":469,"PHASE1":482,"PHASE2":484,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":470,"activeCount":123,"soonestReadout":65},[471],{"nctId":63,"briefTitle":64,"status":139,"phases":472,"primaryCompletion":65,"completion":65,"start":473,"enrollment":11,"conditions":474,"interventions":481},[83],"2025-12-16",[475,476,477,344,478,479,480],"CNS Malignancies","Medulloblastoma Recurrent","ATRT Recurrent","Embryonal Neoplasm","Ependymoma Recurrent","High Grade Gliomas",[66,467],{"trials":483,"activeCount":96},[],{"trials":485,"activeCount":96},[486],{"nctId":487,"briefTitle":488,"status":489,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":501},"NCT05302921","Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed\u002FRefractory Pediatric Solid Tumors","COMPLETED",[85],"2024-03-12","2022-02-18",5,[495,20,18,496,497,498,499,500,272,22],"Osteosarcoma","Relapsed Pediatric Solid Tumor","Refractory Pediatric Solid Tumor","Melanoma","Hepatoblastoma","Hepatocellular Carcinoma",[467,502],"Ipilimumab",{"trials":504,"activeCount":96},[],{"trials":506,"activeCount":96},[],{"trials":508,"activeCount":96},[],{"intervention":66,"totalTrials":123,"cells":510},{"EARLY_PHASE1":511,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":512,"activeCount":123,"soonestReadout":65},[513],{"nctId":63,"briefTitle":64,"status":139,"phases":514,"primaryCompletion":65,"completion":65,"start":473,"enrollment":11,"conditions":515,"interventions":516},[83],[475,476,477,344,478,479,480],[66,467],{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":96},[],{"trials":522,"activeCount":96},[],{"trials":524,"activeCount":96},[],{"trials":526,"activeCount":96},[],{"intervention":528,"totalTrials":9,"cells":529},"Dexmedetomidine",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":551,"NA":574},{"trials":531,"activeCount":96},[],{"trials":533,"activeCount":96},[],{"trials":535,"activeCount":96},[],{"trials":537,"activeCount":96},[538],{"nctId":539,"briefTitle":540,"status":489,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":550},"NCT00480740","The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease",[86],"2011-10","2006-12",41,[546,547,548,549],"Cardiac Transplant","Patent Ductus Arterious","Atrial Septal Defect","Bidirectional Cavopulmonary Anastomosis",[528],{"trials":552,"activeCount":96},[553,565],{"nctId":554,"briefTitle":555,"status":489,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT00654329","Dexmedetomidine vs Fentanyl for BMT",[87],"2008-12","2005-08",101,[561],"Otitis",[563,564,528,528],"Saline","Fentanyl",{"nctId":566,"briefTitle":567,"status":489,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":559,"conditions":571,"interventions":573},"NCT00654511","Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy",[87],"2008-10","2005-01",[572],"Tonsillitis",[564,564,528,528],{"trials":575,"activeCount":96},[],{"intervention":564,"totalTrials":92,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":596},{"trials":579,"activeCount":96},[],{"trials":581,"activeCount":96},[],{"trials":583,"activeCount":96},[],{"trials":585,"activeCount":96},[],{"trials":587,"activeCount":96},[588,592],{"nctId":554,"briefTitle":555,"status":489,"phases":589,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":590,"interventions":591},[87],[561],[563,564,528,528],{"nctId":566,"briefTitle":567,"status":489,"phases":593,"primaryCompletion":569,"completion":569,"start":570,"enrollment":559,"conditions":594,"interventions":595},[87],[572],[564,564,528,528],{"trials":597,"activeCount":96},[],{"intervention":563,"totalTrials":123,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":614},{"trials":601,"activeCount":96},[],{"trials":603,"activeCount":96},[],{"trials":605,"activeCount":96},[],{"trials":607,"activeCount":96},[],{"trials":609,"activeCount":96},[610],{"nctId":554,"briefTitle":555,"status":489,"phases":611,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":612,"interventions":613},[87],[561],[563,564,528,528],{"trials":615,"activeCount":96},[],{"intervention":617,"totalTrials":123,"cells":618},"Dextromethorphan",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":639},{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":96},[],{"trials":624,"activeCount":96},[],{"trials":626,"activeCount":96},[],{"trials":628,"activeCount":96},[629],{"nctId":630,"briefTitle":631,"status":104,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":96,"conditions":635,"interventions":636},"NCT00513864","Assessment of Opioid Analgesia in Sickle Cell",[87],"2012-03","2006-11",[15],[617,637,638],"Codeine","Morphine",{"trials":640,"activeCount":96},[],{"intervention":637,"totalTrials":123,"cells":642},{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":657},{"trials":644,"activeCount":96},[],{"trials":646,"activeCount":96},[],{"trials":648,"activeCount":96},[],{"trials":650,"activeCount":96},[],{"trials":652,"activeCount":96},[653],{"nctId":630,"briefTitle":631,"status":104,"phases":654,"primaryCompletion":633,"completion":633,"start":634,"enrollment":96,"conditions":655,"interventions":656},[87],[15],[617,637,638],{"trials":658,"activeCount":96},[],{"intervention":638,"totalTrials":123,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":96},[],{"trials":664,"activeCount":96},[],{"trials":666,"activeCount":96},[],{"trials":668,"activeCount":96},[],{"trials":670,"activeCount":96},[671],{"nctId":630,"briefTitle":631,"status":104,"phases":672,"primaryCompletion":633,"completion":633,"start":634,"enrollment":96,"conditions":673,"interventions":674},[87],[15],[617,637,638],{"trials":676,"activeCount":96},[],{"intervention":678,"totalTrials":123,"cells":679},"Tylenol",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":700,"NA":702},{"trials":681,"activeCount":96},[],{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[688],{"nctId":689,"briefTitle":690,"status":691,"phases":692,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":699},"NCT03192566","Acetaminophen Dosing in Obese Adolescents","SUSPENDED",[86],"2024-08","2025-09","2016-08",6,[698],"Obesity, Childhood",[678],{"trials":701,"activeCount":96},[],{"trials":703,"activeCount":96},[],{"intervention":705,"totalTrials":123,"cells":706},"Zavesca",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":727,"NA":729},{"trials":708,"activeCount":96},[],{"trials":710,"activeCount":96},[],{"trials":712,"activeCount":96},[],{"trials":714,"activeCount":96},[715],{"nctId":716,"briefTitle":717,"status":489,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":726},"NCT00672022","Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses",[86],"2007-08","2004-07",10,[723,724,725],"GM2 Gangliosidoses","Tay-Sachs","Sandhoff Disease",[705],{"trials":728,"activeCount":96},[],{"trials":730,"activeCount":96},[],{"intervention":732,"totalTrials":92,"cells":733},"Hydroxyurea",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":96},[],{"trials":739,"activeCount":96},[740,749],{"nctId":741,"briefTitle":742,"status":489,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT03644953","Hydroxyurea and Transfusion",[85],"2021-07-01","2018-10-30",14,[15],[732],{"nctId":750,"briefTitle":751,"status":104,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":96,"conditions":755,"interventions":757},"NCT02090296","Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study",[85],"2015-06","2014-02",[756],"Sickle Cell Anemia",[732],{"trials":759,"activeCount":96},[],{"trials":761,"activeCount":96},[],{"trials":763,"activeCount":96},[],{"intervention":765,"totalTrials":123,"cells":766},"intramuscular benzathine penicillin G (BPG) prophylaxis",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":768,"activeCount":96},[],{"trials":770,"activeCount":96},[],{"trials":772,"activeCount":96},[773],{"nctId":774,"briefTitle":775,"status":776,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":786},"NCT03346525","Determining the Impact of Penicillin in Latent RHD: The GOAL Trial","UNKNOWN",[85],"2020-11-30","2018-06-26",807,[782,783,784,785],"Rheumatic Heart Disease in Children","Latent Rheumatic Heart Disease","Rheumatic Heart Disease","Heart Diseases",[765],{"trials":788,"activeCount":96},[],{"trials":790,"activeCount":96},[],{"trials":792,"activeCount":96},[],{"intervention":794,"totalTrials":123,"cells":795},"Caffeine",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[802],{"nctId":803,"briefTitle":804,"status":489,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":811},"NCT03321734","Intermittent Hypoxia and Caffeine in Infants Born Preterm",[85],"2023-06-01","2019-01-18",170,[810],"Intermittent Hypoxia",[794,812],"Placebos",{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"intervention":812,"totalTrials":123,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":822,"activeCount":96},[],{"trials":824,"activeCount":96},[],{"trials":826,"activeCount":96},[827],{"nctId":803,"briefTitle":804,"status":489,"phases":828,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":829,"interventions":830},[85],[810],[794,812],{"trials":832,"activeCount":96},[],{"trials":834,"activeCount":96},[],{"trials":836,"activeCount":96},[],{"intervention":502,"totalTrials":123,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":96},[],{"trials":842,"activeCount":96},[],{"trials":844,"activeCount":96},[845],{"nctId":487,"briefTitle":488,"status":489,"phases":846,"primaryCompletion":491,"completion":491,"start":492,"enrollment":493,"conditions":847,"interventions":848},[85],[495,20,18,496,497,498,499,500,272,22],[467,502],{"trials":850,"activeCount":96},[],{"trials":852,"activeCount":96},[],{"trials":854,"activeCount":96},[],{"intervention":856,"totalTrials":123,"cells":857},"Lyso-thermosensitive Liposomal Doxorubicin",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[864],{"nctId":865,"briefTitle":866,"status":104,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":96,"conditions":870,"interventions":876},"NCT04791228","A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors",[85],"2024-12-23","2022-11-10",[387,871,20,872,18,22,873,874,875],"Soft Tissue Sarcoma","Malignant Epithelial Neoplasm","Hepatic Tumor","Germ Cell Tumor","Bone Metastases",[856],{"trials":878,"activeCount":96},[],{"trials":880,"activeCount":96},[],{"trials":882,"activeCount":96},[],{"intervention":113,"totalTrials":123,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":886,"activeCount":96},[],{"trials":888,"activeCount":96},[],{"trials":890,"activeCount":96},[891],{"nctId":102,"briefTitle":103,"status":104,"phases":892,"primaryCompletion":106,"completion":107,"start":108,"enrollment":96,"conditions":893,"interventions":894},[85],[110,111],[113,91],{"trials":896,"activeCount":96},[],{"trials":898,"activeCount":96},[],{"trials":900,"activeCount":96},[],{"intervention":902,"totalTrials":123,"cells":903},"Melatonin 3 MG",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[],{"trials":909,"activeCount":96},[910],{"nctId":911,"briefTitle":912,"status":776,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":920},"NCT04731974","Acute Concussion and Melatonin",[85],"2024-06-30","2023-03-01",254,[918,919,30],"Concussion, Mild","Concussion, Brain",[902],{"trials":922,"activeCount":96},[],{"trials":924,"activeCount":96},[],{"trials":926,"activeCount":96},[],{"intervention":928,"totalTrials":123,"cells":929},"Canakinumab Injection [Ilaris]",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":931,"activeCount":96},[],{"trials":933,"activeCount":96},[],{"trials":935,"activeCount":96},[936],{"nctId":937,"briefTitle":938,"status":776,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":9,"conditions":942,"interventions":944},"NCT03936894","Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy",[84,85],"2024-04","2019-05-01",[943],"Duchenne Muscular Dystrophy",[928],{"trials":946,"activeCount":96},[],{"trials":948,"activeCount":96},[],{"trials":950,"activeCount":96},[],{"intervention":952,"totalTrials":123,"cells":953},"Cytotoxic T lymphocytes (CTLs).",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[958],{"nctId":959,"briefTitle":960,"status":489,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":721,"conditions":964,"interventions":968},"NCT01923766","Cytotoxic T Cells to Prevent Virus Infections",[84],"2020-03-25","2013-09",[965,966,967],"CMV","EBV","Adenovirus Infections",[952],{"trials":970,"activeCount":96},[],{"trials":972,"activeCount":96},[],{"trials":974,"activeCount":96},[],{"trials":976,"activeCount":96},[],{"intervention":978,"totalTrials":123,"cells":979},"Frameshift Array blood sample test",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"trials":985,"activeCount":96},[],{"trials":987,"activeCount":96},[],{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[992],{"nctId":993,"briefTitle":994,"status":489,"phases":995,"primaryCompletion":996,"completion":996,"start":997,"enrollment":998,"conditions":999,"interventions":1001},"NCT04212351","Frameshift Peptides of Children With NF1",[],"2022-04-27","2019-04-11",60,[1000],"Neurofibromatosis Type 1",[978],{"intervention":1003,"totalTrials":123,"cells":1004},"Dose adjustment of Kaletra",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1006,"activeCount":96},[],{"trials":1008,"activeCount":96},[],{"trials":1010,"activeCount":96},[],{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[],{"trials":1016,"activeCount":96},[1017],{"nctId":1018,"briefTitle":1019,"status":1020,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT00207948","Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents","TERMINATED",[],"2009-05","2009-07","2004-11",4,[1027],"HIV Infections",[1003],{"intervention":1030,"totalTrials":123,"cells":1031},"D-Galactose",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1033,"activeCount":96},[],{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"trials":1039,"activeCount":96},[],{"trials":1041,"activeCount":96},[],{"trials":1043,"activeCount":96},[1044],{"nctId":1045,"briefTitle":1046,"status":489,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":16,"conditions":1050,"interventions":1053},"NCT01113385","Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome",[88],"2013-03","2009-10",[1051,1052],"Focal Segmental Glomerulosclerosis","Steroid Resistant Nephrotic Syndrome",[1030],{"intervention":1055,"totalTrials":123,"cells":1056},"sapropterin dihydrochloride",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1058,"activeCount":96},[],{"trials":1060,"activeCount":96},[],{"trials":1062,"activeCount":96},[],{"trials":1064,"activeCount":96},[],{"trials":1066,"activeCount":96},[],{"trials":1068,"activeCount":96},[1069],{"nctId":1070,"briefTitle":1071,"status":104,"phases":1072,"primaryCompletion":633,"completion":1073,"start":1074,"enrollment":96,"conditions":1075,"interventions":1077},"NCT01412437","Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria",[88],"2012-12","2011-04",[1076],"PKU",[1055,1055]]